Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Liabilities from Discontinued Operations (2016)

Protalix BioTherapeutics (PLX) has 2 years of Liabilities from Discontinued Operations data on record, last reported at 293000.0 in Q2 2016.

  • For Q2 2016, Liabilities from Discontinued Operations changed N/A year-over-year to 293000.0; the TTM value through Jun 2016 reached 293000.0, changed N/A, while the annual FY2014 figure was 52830000.0, N/A changed from the prior year.
  • Liabilities from Discontinued Operations reached 293000.0 in Q2 2016 per PLX's latest filing, down from 52830000.0 in the prior quarter.
  • Across five years, Liabilities from Discontinued Operations topped out at 52830000.0 in Q4 2014 and bottomed at 293000.0 in Q2 2016.